Fatal bilateral intracerebral hemorrhage following treatment with alemtuzumab for multiple sclerosis

BackgroundAlemtuzumab is approved for treating multiple sclerosis. It can, however, cause intracerebral hemorrhage (ICH) mediated by an immune thrombocytopenia. So far, only one fatal case of ICH following alemtuzumab treatment in apatient with a normal platelet count has been reported. Aconnection to alemtuzumab could, however, not be verified because no autopsy was performed on the deceased.ObjectiveThe main objective of this article is to report the case of apatient with normal platelet count, who suffered afatal bilateral ICH shortly after treatment with alemtuzumab was initiated. Histological signs of increased vascular permeability were found.ConclusionUnder consideration of the clinical cause and the neuropathological findings, it is suggested that acausal connection exists between the alemtuzumab treatment and the ICH, which was possibly mediated by vascular damage.     «

BackgroundAlemtuzumab is approved for treating multiple sclerosis. It can, however, cause intracerebral hemorrhage (ICH) mediated by an immune thrombocytopenia. So far, only one fatal case of ICH following alemtuzumab treatment in apatient with a normal platelet count has been reported. Aconnection to alemtuzumab could, however, not be verified because no autopsy was performed on the deceased.ObjectiveThe main objective of this article is to report the case of apatient with normal platelet count...     »